U.S. Markets close in 4 hrs 57 mins

Vical Inc (VICL) Files 10-K for the Fiscal Year Ended on December 31, 2018

- By insider

Vical Inc (VICL) files its latest 10-K with SEC for the fiscal year ended on December 31, 2018. Vical Inc is engaged in research and development of biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. Vical Inc has a market cap of $22.471 million; its shares were traded at around $1.03 with and P/S ratio of 3.53. Vical Inc had annual average EBITDA growth of 21.60% over the past ten years.


For the last quarter Vical Inc reported a revenue of $0.12 million, compared with the revenue of $3.95 million during the same period a year ago. For the latest fiscal year the company reported a revenue of $1.62 million, a decrease of 88.3% from the previous year. For the last five years Vical Inc had an average revenue decline of 21.5% a year.

The reported loss per diluted share was 74 cents for the year, compared with the loss per share of $1.86 in the previous year. The Vical Inc had an operating margin of -1211.22%, compared with the operating margin of -96.87% a year before. The 10-year historical median operating margin of Vical Inc is -121.51%. The profitability rank of the company is 2 (out of 10).

At the current stock price of $1.03, Vical Inc is traded at 59.1% discount to its historical median P/S valuation band of $2.52. The P/S ratio of the stock is 3.53, while the historical median P/S ratio is 8.65. The stock lost 32.68% during the past 12 months.

For the complete 20-year historical financial data of VICL, click here.

This article first appeared on GuruFocus.